UY37449A - Anticuerpos anti-chikv y usos de éstos - Google Patents

Anticuerpos anti-chikv y usos de éstos

Info

Publication number
UY37449A
UY37449A UY0001037449A UY37449A UY37449A UY 37449 A UY37449 A UY 37449A UY 0001037449 A UY0001037449 A UY 0001037449A UY 37449 A UY37449 A UY 37449A UY 37449 A UY37449 A UY 37449A
Authority
UY
Uruguay
Prior art keywords
antibodies
chikv
relates
disease
chikv antibodies
Prior art date
Application number
UY0001037449A
Other languages
English (en)
Inventor
Kara Carter
Cendrine Lemoine
Marie Mandron
Huawei Qiu
Jonathan Rothblatt
Sunghae Park
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of UY37449A publication Critical patent/UY37449A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1081—Togaviridae, e.g. flavivirus, rubella virus, hog cholera virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere a anticuerpos y fragmentos de unión a antígeno de anticuerpos que se unen específicamente a y neutralizan el virus Chikungunya (CHIKV) y que se preparan por ingeniería para desarrollar terapéuticos con el fin de tratar la enfermedad CHIKV o prevenir la infección con CHIKV. La invención también se refiere a composiciones farmacéuticas que comprenden anticuerpos de la invención y al uso de los anticuerpos para la prevención y tratamiento de la enfermedad CHIKV.
UY0001037449A 2016-10-20 2017-10-20 Anticuerpos anti-chikv y usos de éstos UY37449A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP16306374 2016-10-20

Publications (1)

Publication Number Publication Date
UY37449A true UY37449A (es) 2018-05-31

Family

ID=57590434

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001037449A UY37449A (es) 2016-10-20 2017-10-20 Anticuerpos anti-chikv y usos de éstos

Country Status (12)

Country Link
US (2) US11286295B2 (es)
EP (1) EP3529271A1 (es)
JP (2) JP7181193B6 (es)
CN (2) CN110088131B (es)
AR (1) AR109857A1 (es)
CA (1) CA3040842A1 (es)
EA (1) EA201990988A1 (es)
IL (2) IL266082B1 (es)
MA (1) MA46562A (es)
TW (2) TWI778985B (es)
UY (1) UY37449A (es)
WO (1) WO2018073387A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA41517A (fr) 2015-04-14 2017-12-19 Univ Vanderbilt Neutralisation du virus du chikungunya à médiation par des anticorps
US11286295B2 (en) 2016-10-20 2022-03-29 Sanofi Anti-CHIKV monoclonal antibodies directed against the E2 structural protein
EP3735589A2 (en) 2018-01-05 2020-11-11 Vanderbilt University Antibody-mediated neutralization of chikungunya virus
KR102201261B1 (ko) * 2019-05-15 2021-01-11 한국생명공학연구원 치쿤구니야 바이러스에 특이적인 단일클론 항체 및 이의 용도
CN114656554B (zh) * 2022-03-07 2023-05-23 中山大学 基孔肯雅热病毒e2蛋白的纳米抗体及其应用

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
EP0247091B1 (en) 1985-11-01 1993-09-29 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
EP0272253A4 (en) 1986-03-07 1990-02-05 Massachusetts Inst Technology METHOD FOR IMPROVING GLYCOPROTE INSTABILITY.
US4861719A (en) 1986-04-25 1989-08-29 Fred Hutchinson Cancer Research Center DNA constructs for retrovirus packaging cell lines
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5202238A (en) 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
US5278056A (en) 1988-02-05 1994-01-11 The Trustees Of Columbia University In The City Of New York Retroviral packaging cell lines and process of using same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5670488A (en) 1992-12-03 1997-09-23 Genzyme Corporation Adenovirus vector for gene therapy
ATE255131T1 (de) 1991-06-14 2003-12-15 Genentech Inc Humanisierter heregulin antikörper
AU6248994A (en) 1993-02-22 1994-09-14 Rockefeller University, The Production of high titer helper-free retroviruses by transient transfection
FR2712812B1 (fr) 1993-11-23 1996-02-09 Centre Nat Rech Scient Composition pour la production de produits thérapeutiques in vivo.
IL116816A (en) 1995-01-20 2003-05-29 Rhone Poulenc Rorer Sa Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof
JP3946256B2 (ja) 1995-09-11 2007-07-18 協和醗酵工業株式会社 ヒトインターロイキン５受容体α鎖に対する抗体
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
JP2001522241A (ja) 1997-04-10 2001-11-13 ロイヤル ネザーランズ アカデミー オブ アーツ アンド サイエンシズ 診断方法および試薬
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
PL220113B1 (pl) 1999-01-15 2015-08-31 Genentech Inc Wariant macierzystego polipeptydu zawierającego region Fc, polipeptyd zawierający wariant regionu Fc o zmienionym powinowactwie wiązania receptora Fc gamma (FcγR), polipeptyd zawierający wariant regionu Fc o zmienionym powinowactwie wiązania noworodkowego receptora Fc (FcRn), kompozycja, wyizolowany kwas nukleinowy, wektor, komórka gospodarza, sposób otrzymywania wariantu polipeptydu, zastosowanie wariantu polipeptydu i sposób otrzymywania wariantu regionu Fc
ES2727425T3 (es) 2000-12-12 2019-10-16 Medimmune Llc Moléculas con semividas prolongadas, composiciones y usos de las mismas
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
US8802820B2 (en) * 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
US8546543B2 (en) 2004-11-12 2013-10-01 Xencor, Inc. Fc variants that extend antibody half-life
JP4652414B2 (ja) * 2004-11-12 2011-03-16 ゼンコー・インコーポレイテッド ＦｃＲｎとの変化した結合を有するＦｃ変異体
WO2006067122A2 (en) * 2004-12-20 2006-06-29 Crucell Holland B.V. Binding molecules capable of neutralizing west nile virus and uses thereof
CA2545597A1 (en) 2006-03-15 2007-09-15 Institut Pasteur Novel isolated and purified strains of chikungunya virus and polynucleotides and polypeptides sequences, diagnostic and immunogenical uses thereof
CA2598966A1 (en) 2007-09-07 2009-03-07 Institut Pasteur Anti-chikungunya monoclonal antibodies and uses thereof
EP2050764A1 (en) 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
PL2808343T3 (pl) 2007-12-26 2019-11-29 Xencor Inc Warianty Fc ze zmienionym wiązaniem do FcRn
KR101290503B1 (ko) * 2008-01-17 2013-07-26 아이알엠 엘엘씨 개선된 항-ｔｒｋｂ 항체
US9441032B2 (en) 2010-04-07 2016-09-13 Agency For Science, Technology And Research Binding molecules against Chikungunya virus and uses thereof
EP2374816B1 (en) 2010-04-07 2016-09-28 Agency For Science, Technology And Research Binding molecules against Chikungunya virus and uses thereof
WO2012106578A1 (en) 2011-02-04 2012-08-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services HIV NEUTRALIZING ANTIBODIES HAVING MUTATIONS IN CONSTANT DOMAIN (Fc)
GB201112429D0 (en) * 2011-07-19 2011-08-31 Glaxo Group Ltd Antigen-binding proteins with increased FcRn binding
CA2889723A1 (en) 2012-12-13 2014-06-19 The Trustees Of The University Of Pennsylvania Dna antibody constructs and method of using same
EP3021868A4 (en) 2013-07-19 2017-03-01 Integral Molecular, Inc. Antibodies against chikungunya virus and uses thereof
MA41517A (fr) 2015-04-14 2017-12-19 Univ Vanderbilt Neutralisation du virus du chikungunya à médiation par des anticorps
US11286295B2 (en) 2016-10-20 2022-03-29 Sanofi Anti-CHIKV monoclonal antibodies directed against the E2 structural protein

Also Published As

Publication number Publication date
EP3529271A1 (en) 2019-08-28
US20220275063A1 (en) 2022-09-01
US20180127487A1 (en) 2018-05-10
EA201990988A1 (ru) 2019-09-30
IL266082A (en) 2019-06-30
CN110088131A (zh) 2019-08-02
TW201827461A (zh) 2018-08-01
JP2023015301A (ja) 2023-01-31
WO2018073387A1 (en) 2018-04-26
TW202300515A (zh) 2023-01-01
CN110088131B (zh) 2022-12-06
JP7181193B2 (ja) 2022-11-30
IL310834A (en) 2024-04-01
CN115873106A (zh) 2023-03-31
TWI778985B (zh) 2022-10-01
US11286295B2 (en) 2022-03-29
JP7181193B6 (ja) 2022-12-13
IL266082B1 (en) 2024-03-01
CA3040842A1 (en) 2018-04-26
AR109857A1 (es) 2019-01-30
MA46562A (fr) 2019-08-28
JP2019534001A (ja) 2019-11-28

Similar Documents

Publication Publication Date Title
CL2022003763A1 (es) Anticuerpos humanos contra glicoproteína del virus ébola
CO2017006580A2 (es) Anticuerpos humanos para hemaglutinina de influenza
UY37336A (es) Anticuerpos anti-virus del zika y métodos de uso
UY37449A (es) Anticuerpos anti-chikv y usos de éstos
ECSP18005520A (es) Anticuerpos de factor xi y métodos de uso
BR112017000664A2 (pt) anticorpo anti-pd-1 e seu uso
EA201891186A1 (ru) Антитела, нейтрализующие вирус иммунодефицита человека
CR20190403A (es) Una composición farmacéutica que comprende un anticuerpo anti-c5 contra una enfermedad relacionada con c5 y un producto de la misma
UY36905A (es) Anticuerpos neutralizantes de poliomavirus
CL2017002596A1 (es) Neutralización del virus chikungunya mediada por anticuerpos
CO2020002060A2 (es) Anticuerpos multiespecíficos que se unen específicamente a los epítopos del virus del zika y usos de los mismos
BR112018005905A2 (pt) ?composto, composição farmacêutica, métodos para evitar ou tratar uma doença ou condição, lesões de órgão, hepatotoxicidade e fígado gorduroso, e, uso de um composto?
GT201600250A (es) Compuestos de 1, 3, 4- tiadiazol y uso de los mismos para el tratamiento del cáncer
BR112018070302A2 (pt) agentes que reconhecem o epítopo de clever-1 e usos dos mesmos
CL2021000258A1 (es) Anticuerpos anti-btn3a y su uso en el tratamiento del cáncer o trastornos infecciosos.
BR112022008365A2 (pt) Inibidores de cd73
UY36262A (es) Anticuerpos anti proteína similar a angiopoyetina 4 y métodos de uso
BR112016015078A2 (pt) método para prevenir ou tratar infecção por vírus influenza a h7n9, uso do anticorpo e composição farmacêutica
BR112018001907A2 (pt) uso de anticorpos anti-cd40 para o tratamento de nefrite lúpica
CL2017003260A1 (es) Dominios variables simples de inmunoglobulina contra proteína f de rsv.
BR132018069012E2 (pt) uso de anticorpos policlonais humanos ou fragmentos destes, e, composição farmacêutica
EA201990041A1 (ru) Композиции, содержащие тимолол, и их применение при лечении розацеа при местном применении
BR112017019816A2 (pt) compostos, composição farmacêutica, método para o tratamento profilático ou terapêutico de doença dos rins e/ou fígado em um sujeito, e uso de um composto
EA201301340A1 (ru) Фармацевтическая композиция, обладающая нейропротекторным действием, её применение и способы повышения жизнеспособности и профилактики или лечения цереброваскулярных и нейродегенеративных заболеваний
CL2016000915A1 (es) Uso de una composición que comprende al menos un anticuerpo monoclonal humanizado o moléculas neutralizantes que neutralizan la función de las moléculas tslp y/o tslpr y/o ox40l y/o cd177, para preparar un medicamento para el tratamiento o para aminorar los síntomas y enfermedad de pacientes infectados con el metapneumovirus humano (hmpv)